Abstract
Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis
Volume: 8 Issue: 1
Author(s): D. Digiuseppe and C. Feliciani
Affiliation:
Keywords: Psoriasis, therapy, anti TNF, biological agents, tumor necrosis factor
Abstract: Psoriasis has been for a long time a distressing skin disease difficult to treat. Several topical and systemic drugs have been used successfully in the treatment but the most active drugs are also the most difficult to manage in a long term treatment. Discovering the pathogenesis of this skin disorder has suggested that anti tumor necrosis factors agents could be an alternative treatment. Up to now several manuscripts show data supporting the idea that anti TNF are safe and effective more than other drugs. On the experience of dermatologists using this drug in a large number of patients TNF inhibitors are very effective drugs with a relatively safe management. At the moment several drug companies are developing a second generation of biologic drugs with different targets. This review point out the actual knowledge about anti TNF drugs and their activities on psoriasis both clinically and biologically.
Export Options
About this article
Cite this article as:
Digiuseppe D. and Feliciani C., Tumor Necrosis Factor Inhibitors as Therapeutic Choice in Psoriasis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2009; 8 (1) . https://dx.doi.org/10.2174/187152309787580766
DOI https://dx.doi.org/10.2174/187152309787580766 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Disease Progression in Children with Vertically-Acquired HIV Infection in Sub-Saharan Africa: Reviewing the Need for HIV Treatment
Current HIV Research Subdural Pharmacotherapy for the Treatment of Intractable Focal Neocortical Epilepsy
Drug Delivery Letters Beneficial and Adverse Effects of Molecularly Targeted Therapies for Acute Promyelocytic Leukemia in Central Nervous System
CNS & Neurological Disorders - Drug Targets Are Circulating Monocytes as Microglia Orthologues Appropriate Biomarker Targets for Neuronal Diseases? (Supplementry Table)
Central Nervous System Agents in Medicinal Chemistry High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research An Overview of Antiretroviral Agents for Treating HIV Infection in Paediatric Population
Current Medicinal Chemistry Lignans and Neolignans Anti-tuberculosis Identified by QSAR and Molecular Modeling
Combinatorial Chemistry & High Throughput Screening Lassa Virus Genome
Current Genomics Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Recent Patents in CNS Drug Discovery: The Management of Inflammation in the Central Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Immune Responses to Adenovirus and Adeno-Associated Vectors Used for Gene Therapy of Brain Diseases: The Role of Immunological Synapses in Understanding the Cell Biology of Neuroimmune Interactions
Current Gene Therapy Pathogenesis of Central Nervous System Tuberculosis
Current Molecular Medicine Cranial Ultrasound - Optimizing Utility in the NICU
Current Pediatric Reviews A Retrospective Study on the Incidence of Seizures among Neurosurgical Patients Who Treated with Imipenem/Cilastatin or Meropenem
Current Pharmaceutical Biotechnology The Epidemiological and Pangenome Landscape of <i>Staphylococcus aureus</i> and Identification of Conserved Novel Candidate Vaccine Antigens
Current Proteomics A Review on Hematopoietic Stem Cell Treatment for Epilepsy
CNS & Neurological Disorders - Drug Targets Functions of S100 Proteins
Current Molecular Medicine Editorial [Is Drug Safety Dangerous?]
Current Drug Safety Proteomic Analysis of Differentially Expressed Proteins in <i>Mycobacterium Tuberculosis</i>-Infected Macrophages
Current Proteomics Targeting the Methyl Erythritol Phosphate (MEP) Pathway for Novel Antimalarial, Antibacterial and Herbicidal Drug Discovery: Inhibition of 1-Deoxy-D-Xylulose-5-Phosphate Reductoisomerase (DXR) Enzyme
Current Pharmaceutical Design